Most patients with HCV-associated lymphoma present with mild liver disease: A call to revise antiviral treatment prioritization

Liver International

Volumn 35, Issue 6, 2015, Pages 1661-1664

  Torres, Harrys A ^a   Mahale, Parag ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Antiviral therapy; Hepatitis C virus; Liver fibrosis; Non Hodgkin lymphoma

Indexed keywords

INTERFERON; RIBAVIRIN; VIRUS RNA; ANTIVIRUS AGENT;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; B CELL LYMPHOMA; CANCER PATIENT; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HUMAN; LARGE CELL LYMPHOMA; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; RADIOGRAPHY; COMPLICATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; LIVER; LIVER CIRRHOSIS; MIDDLE AGED; NONHODGKIN LYMPHOMA; PATHOLOGY; VIROLOGY;

ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED;

EID: 84929133645     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12825     Document Type: Article

References (16)

1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-73.
2. Lee MH, Yang HI, Lu SN, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012; 206: 469-77.
3. Peveling-Oberhag J, Arcaini L, Hansmann ML, Zeuzem S. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol 2013; 59: 169-77.
4. Hartridge-Lambert SK, Stein EM, Markowitz AJ, Portlock CS. Hepatitis C and non-Hodgkin lymphoma: the clinical perspective. Hepatology 2012; 55: 634-41.
5. Cacoub P, Gragnani L, Comarmond C, Zignego AL. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis 2014; 46S: S165-73.
6. Paydas S. Hepatitis C virus and lymphoma. Crit Rev Oncol Hematol 2015; 93: 246-56.
7. Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: systematic review and meta-analysis. Gastroenterology 2003; 125: 1723-32.
8. Arcaini L, Vallisa D, Rattotti S, et al. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. Ann Oncol 2014; 25: 1404-10.
9. Kawamura Y, Ikeda K, Arase Y, et al. Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med 2007; 120: 1034-41.
10. AASLD/IDSA/IAS-USA. When and in whom to initiate HCV therapy. Recommendations for testing, managing, and treating hepatitis C. Available from: http://www.hcvguidelines.org/full-report/when-and-whom-initiate-hcv-therapy (accessed 7 March 2014).
11. Nieters A, Kallinowski B, Brennan P, et al. Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH. Gastroenterology 2006; 131: 1879-86.
12. Kasama Y, Sekiguchi S, Saito M, et al. Persistent expression of the full genome of hepatitis C virus in B cells induces spontaneous development of B-cell lymphomas in vivo. Blood 2010; 116: 4926-33.
13. Degasperi E, Aghemo A. Clinical drivers in naive patient eligibility for treatment of chronic hepatitis C. J Viral Hepat 2012; 19(Suppl 1): 3-6.
14. Ghany MG. The ongoing debate of who to treat for chronic hepatitis C virus. JAMA Intern Med 2015; 175: 169-70.
15. Butt AA, Yan P, Lo Re V 3rd, et al. Liver fibrosis progression in hepatitis C virus infection after seroconversion. JAMA Intern Med 2015; 175: 178-85.
16. Liang TJ, Ghany MG. Therapy of hepatitis C-back to the future. N Engl J Med 2014; 370: 2043-7.